Tumor cells: what are they and how are they different?

A tumor cell is a cell in our body that has escaped the control of regulatory signals: it divides when it shouldn't; it doesn't "listen" to orders to stop; it doesn't die as planned, even if damaged; it can invade neighboring tissues and spread throughout the body. These differences don't accumulate immediately: first, the cell acquires one or two "breakdowns," then variants more favorable for survival are selected and consolidated—step by step, a population of cells with deviant properties emerges. It is these properties, not their "foreignness," that make cancer dangerous and distinguish it from benign growths. [1]

Normally, cells strictly obey tissue "rules": they divide on command, stop when in contact with neighbors, die if damaged, and do not migrate. Tumor cells violate these rules—they act as "bad neighbors," breaking tight junctions, producing their own growth factors, and reshaping the tissue "ecosystem" around them. At the molecular level, this reflects genetic breakdowns (mutations, chromosome rearrangements) and epigenetic shifts (gene reprogramming). [2]

It's important to understand that a tumor cell is not a "foreign body." It's our own cell, which has gone on an evolutionary "motorcycle": it utilizes all the survival mechanisms of a multicellular organism, but to its own advantage. Therefore, cancer simultaneously resembles a "mini-evolution" within the body and a malfunction in the control of a complex tissue system. This duality explains both the diversity of clinical forms and the different responses to therapy. [3]

Finally, a tumor cell is not a static entity, but a dynamic process. Cells within different areas of the same tumor can differ radically: some rapidly divide, others remain dormant, and still others are capable of migration; some even change under the pressure of therapy. This phenomenon is called intratumor heterogeneity and is directly linked to relapse and drug resistance. [4]

Basic properties ("signs of cancer")

Over the past decades, oncology has come to agree on a core set of characteristics by which we recognize tumor cells. This set is known as the "Hallmarks of Cancer": robust division without external cues, evasion of anti-growth barriers, resistance to "programmed cell death," limitless cell division potential, stimulation of vascular growth, and the ability to invade and metastasize. These are complemented by "enabling" properties—genomic instability and inflammation—as well as new dimensions: immune evasion, metabolic restructuring, phenotypic plasticity, and the influence of aging and the microbiome. This provides a useful "map" for understanding how a normal cell evolves into a tumor cell. [5]

Sustained cell division is achieved in many ways: the cell can produce growth factors itself, activate their receptors within itself, or "break" the cell cycle brakes. At the same time, it suppresses self-destruction programs—for example, by disabling apoptotic signaling pathways. As a result, even with critical DNA damage, such a cell does not stop or die—it continues to divide and pass on the damage. [6]

"Immortality" is another distinctive feature. Normal cells divide a limited number of times because with each division, telomeres—the protective "caps" on chromosomes—shorten. Tumor cells often activate telomerase or other bypass mechanisms, restoring telomeres and removing the natural limit on division. This is "replicative immortality"—the foundation for the accumulation of mutations and the selection of more aggressive clones. [7]

Finally, tumor cells learn to survive in conditions that would cause normal cells to "surrender": they attract blood vessels (angiogenesis), change their energy production, hide from the immune system, and, when necessary, alter their appearance by weakening intercellular bonds and becoming more mobile. This enables invasion and metastasis—the main cause of cancer mortality. [8]

Metabolic and genetic features

Tumor cell metabolism is skewed: instead of "economical" energy production in mitochondria, they often prefer "fast" aerobic glycolysis—actively consuming glucose and converting it into lactate even in the presence of oxygen. This is the famous Warburg effect. It gives the cell advantages: speed, raw materials for building new molecules, and the ability to survive in oxygen-poor niches. In modern terms, this is a flexible spectrum, not "always and everywhere glycolysis": tumors can switch. [9]

The genetic "soil" for tumor behavior is genomic instability. Failures in DNA repair systems and chromosome division errors lead to chromosomal instability: changes in the number and structure of chromosomes occur, amplifications, deletions, and rearrangements occur. Instability is the "driver" of diversity, from which more adaptable clones are selected; at the same time, too high a level of breakdowns can also harm the tumor itself. This is a delicate evolutionary balance. [10]

A separate issue is replication stress: when DNA division is too rapid, "unfinished" sections accumulate in the cell, replication forks are broken, and mutation rates increase. To survive, tumor cells activate emergency pathways and reprogram DNA damage control—this is one reason why inhibitors of "repair" enzymes (for example, PARP for certain defects) can be selectively toxic to cancer cells. [11]

Metabolic restructuring and genetic instability are closely intertwined: metabolic "shifts" alter the epigenome and gene expression, while mutations alter enzymatic cascades. Together, this creates a flexible yet vulnerable system—and it is precisely in its vulnerabilities that therapeutic targets are sought. [12]

Microenvironment and immune evasion

A tumor isn't just the cells themselves. A special microenvironment forms around them: fibroblasts, vascular cells, immune cells, and the extracellular matrix. The tumor cell "re-educates" its neighbors—forcing fibroblasts to support growth, rebuilding the matrix for invasion, and altering access to oxygen and nutrients. This "satellite city" works to promote tumor survival while simultaneously concealing it from immune surveillance. [13]

A tumor's main line of defense is the suppression of antitumor T cells. One of the key mechanisms is the activation of the PD-1/PD-L1 pathway: the tumor cell or cells in the microenvironment express the PD-L1 ligand, which binds to the PD-1 receptor on the T cell and "inhibits" it. The result is immune tolerance: T cells see the target but do not attack. Blockade of these "checkpoints" (PD-1/PD-L1 and CTLA-4 inhibitors) has become a breakthrough in the treatment of a number of tumors. [14]

Immune evasion is also supported by the "chemistry" of the microenvironment: lactic acid from increased glycolysis acidifies tissue, inhibiting immunity; oxygen and nutrient deficiency depletes T cells; immune suppressors (e.g., regulatory T cells and myeloid-derived suppressor cells) accumulate and "silence" the response. The result is a dual defense system—molecular "brakes" and "ecological" barriers. [15]

Understanding the role of the microenvironment explains why the same drug works differently in different patients. The target may be the same, but the surrounding "landscape" may be different. Therefore, combination approaches are being actively explored today: immunotherapy combined with radiation, antiangiogenic, metabolic, or targeted therapy, to simultaneously "remove the brakes" and "change the landscape." [16]

Evolution, plasticity and heterogeneity

Tumors evolve as a population: new mutations and epigenetic states generate variants, while therapy and immunity "select" those who survive better. Back in 1976, Peter Knowll described the clonal evolution of tumors; modern genomic and single-cell methods have only refined the picture and demonstrated the mosaic nature of real tumors. This is key to understanding relapse: by eliminating a susceptible clone, we leave room for resistant ones. [17]

Plasticity is the ability of a cell to change its "mask." For example, an epithelial cell temporarily loses its contacts and acquires the characteristics of a more mobile mesenchymal cell—a process known as epithelial-mesenchymal transition. This facilitates exit from the primary tumor and colonization of new niches, and can also reduce sensitivity to drugs. In reality, this is not a "switch," but a spectrum of states that cells adopt in response to environmental cues. [18]

A portion of the population may possess stem-like properties—the ability to self-renew and give rise to different progeny. The concept of "cancer stem cells" is not appropriate for all tumors and evolves as data accumulates: what matters is not so much the "presence of a special caste" as the flexible emergence of stem-like states under environmental and therapeutic pressure. This makes targeting such states a moving target. [19]

The result of this dynamic is strong heterogeneity: different tumor sites and different metastases can differ dramatically. Therefore, the role of multifocal biopsies, liquid biopsies (based on tumor DNA traces in the blood), and repeat profiling during progression is growing in diagnostics—to "catch up" with the evolution of tumor cells using facts, not guesswork. [20]

What does this mean for diagnosis and treatment?

Simply put, nearly every "signature" of a tumor cell has become a therapeutic target. Immune checkpoint blockade removes the "brakes" from T cells and teaches the body to see the tumor again. Targeted drugs attack vulnerable nodes in signaling pathways (for example, activated growth drivers). Antiangiogenic approaches "rewire" the vasculature. Metabolic strategies attempt to deprive tumor cells of their energy "hacks." Combining methods allows attacking multiple "pillars" of survival simultaneously. [21]

Diagnostics are increasingly focused on biology, not just anatomy. In addition to histology, mutations and rearrangements, markers of immune interactions, signs of genomic instability, and metabolic characteristics are assessed. This "bioprofiling" helps predict drug response, select clinical trials, and plan the sequence of treatment lines. Ideally, the profile is refined at relapse, as tumor cells change under the pressure of treatment. [22]

However, there is no "magic bullet": due to evolution and heterogeneity, tumor cells almost always find workarounds. This is why treatment strategies are increasingly being developed as "multi-move plans": they immediately plan what to do in the event of a partial response, how to transition the patient to maintenance therapy, and how to intercept emerging resistance. Monitoring, follow-up examinations, multidisciplinary teamwork, and participation in research studies when standard options have been exhausted are essential. [23]

And perhaps the most important practical conclusion: a tumor cell is not only a target but also an indicator of how dynamic cancer is. The better we understand its properties (growth without signals, death evasion, plasticity, immune evasion, genomic instability, metabolic "tricks"), the more accurately we can select combinations of methods and the timing of their application. This is why modern guidelines increasingly rely on the "cancer hallmarks" framework as a common language between the laboratory and the clinic. [24]